Tsai Hsin-Yi, Huang Yu-Wen, Chang Shu-Ya, Huang Li-Ying, Lin Chii Jeng, Lee Po-Chang
Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan.
National Health Insurance Administration, Ministry of Health and Welfare, Taipei, Taiwan.
GMS Health Innov Technol. 2022 Mar 16;16:Doc02. doi: 10.3205/hta000134. eCollection 2022.
Medical technology is undergoing rapid transformations, and the classifications of medical devices have also expanded greatly; therefore, it is necessary to develop appropriate reimbursement policies and pricing mechanisms in a timely manner. This paper aims to introduce the reimbursement coverage and pricing rules for medical devices in Taiwan. In addition, this paper identifies and evaluates available health technology assessments (HTA) and literature on published websites concerning medical device decision-making processes and pricing systems in South Korea and Japan, which are near Taiwan and have similar reimbursement coverage processes. Reimbursement policy and pricing mechanisms are constantly being revised in Taiwan, Japan, and South Korea. Recently, all three countries attempted to establish new reimbursement coverage decision-making and pricing rules, adopting a differentiated approach based on the level of evidence required for the appropriated reimbursement in terms of a feasible evaluation mechanism for providing patients with more effective medical devices. This article is expected to contribute to providing references to new reimbursement coverage decision-making and pricing rules.
医疗技术正在经历快速变革,医疗设备的分类也大幅扩展;因此,及时制定适当的报销政策和定价机制很有必要。本文旨在介绍台湾地区医疗设备的报销范围和定价规则。此外,本文还识别并评估了韩国和日本已发布网站上有关医疗设备决策过程和定价系统的现有卫生技术评估(HTA)及文献,韩国和日本与台湾地区临近且报销范围流程相似。台湾地区、日本和韩国的报销政策和定价机制一直在修订。最近,这三个地区都试图建立新的报销范围决策和定价规则,基于可行的评估机制,根据适当报销所需的证据水平采取差异化方法,以便为患者提供更有效的医疗设备。期望本文能为新的报销范围决策和定价规则提供参考。